Minerva Neurosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2020-06-30 was $346.03K.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2020-03-31 was $797.63K, a 51.93% increase year-over-year.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2019-03-31 was $525.00K.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2018-12-31 was $165.10K.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $1.14M, a 117.84% increase from fiscal 2019.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2019 was $525.00K, a 19.96% decline from fiscal 2018.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2018 was $655.93K, a 41.98% decline from fiscal 2017.
- Minerva Neurosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2017 was $1.13M, a 1373.52% increase from fiscal 2016.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2020-12-31 | $1.14M 10-K · filed 2022-03-01 | |
| 2020-06-30 | $346.03K 10-Q · filed 2021-11-08 | |
| 2020-03-31 | $797.63K 10-Q · filed 2021-11-08 | |
| 2019-12-31 | $525.00K 10-K · filed 2021-03-08 | |
| 2019-03-31 | $525.00K 10-Q · filed 2020-11-02 | |
| 2018-12-31 | $165.10K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $655.93K 10-K · filed 2020-03-09 |
| 2018-09-30 | $490.83K 10-Q · filed 2019-11-04 | |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $1.13M 10-K · filed 2019-03-12 |
| 2017-09-30 | $554.37K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $1.20M derived: sum of 4 quarters · filed 2018-11-05 |
| 2017-06-30 | $294.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | |
| 2017-03-31 | $281.76K 10-Q · filed 2018-05-03 | |
| 2016-12-31 | $66.86K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $76.72K 10-K · filed 2018-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |